Google AI

Weekend Times


The Times

PR Newswire

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

  • Written by: PR Newswire Asia - The Times Au RSS
Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study started at the University Clinic of Navarra, Spain, under the supervision of Pr. Ignacio Melero, Immunologist and Senior Investigator at Centro de Investigación Médica Aplicada (CIMA).

This clinical research is led by Principal Investigator Pr. Aurelien Marabelle of the Gustave Roussy Cancer Institute (Villejuif, France). Pr. Marabelle is the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy and Senior Medical Oncologist within its Drug Development Department (DITEP). The study will involve other sites in France and Spain, including at the Toulouse University Hospital (IUCT) located at the Toulouse-Oncopole Campus.

Aurelien Marabelle said: "VISTA is a new immune-checkpoint molecule highly expressed in the tumor microenvironment. There are great expectations within the medico-scientific community for this new target and its biology. With this clinical study and its extensive translational medicine plan, we are delighted to contribute to improve the knowledge on VISTA for the benefit of cancer patients."

Jean-Luc Lowinski, Pierre Fabre Medical Care CEO, added: "At Pierre Fabre, innovation in oncology is at the top of our strategic priorities and we are all very keen to bring this new molecule to clinical evaluation. Immunotherapy has already been a revolution for cancer patients in many indications, but the medical need is still incredibly huge. Our oncology R&D teams are fully committed to identify and develop innovative therapies for patients who are refractory or resistant to current treatments."

W0180 is a first-in-class antibody targeting VISTA (V-domain Ig suppressor of T cell Activation). VISTA is a negative checkpoint regulator of T cell response. VISTA is expressed within the tumor microenvironment, where its inhibition can enhance antitumor immune responses. Furthermore, an increase in VISTA expression has been reported after treatment by anti-PD1/L1 and anti-CTLA4. This confirms that VISTA may play a key role as a mechanism of resistance to the currently used immunotherapies. W0180 given to patients as a single agent or in combination with anti-PD1/L1 therapy has a potential in multiple cancer indications, including those with myeloid immunosuppressive infiltrates where VISTA pathway is expressed.

Pierre Fabre has presented 3 communications about W0180 to the Annual Meetings of the American Association of Cancer Research (AACR 2019 and AACR 2020) and is preparing an upcoming communication to the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting to be held virtually on November 9-14, 2020. The SITC communication is entitled "W0180 novel anti-VISTA antibody: rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody."

About Pierre Fabre

Pierre Fabre is a French health and beauty care company with 35-year experience in innovation, development, manufacturing and commercialization in oncology. The company has recently reaffirmed oncology as one of its main R&D and commercial priorities, focusing on targeted therapies, biotherapies and immuno-oncology. Its therapeutic areas cover high unmet medical needs, including colorectal, breast, lung cancers, melanoma and pre-cancerous conditions like actinic keratosis.

In 2019, Pierre Fabre generated 2.4 billion euros in revenues, of which two-thirds originated from its international business. Pierre Fabre, which has always been headquartered in the South-West of France, employs approximately 10,400 people worldwide, owns subsidiaries and offices in 45 countries and enjoys distribution agreements in over 130 countries. Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

In 2019, Ecocert Environment assessed the Group's corporate social and environmental responsibility approach according to the ISO 26000 standard on sustainable development and awarded it the ECOCERT 26000 "Excellence" level.

www.pierre-fabre.com[1]@PierreFabre

PRESS CONTACTAnne KERVEILLANT anne.kerveillant@pierre-fabre.com [2]

References

  1. ^ www.pierre-fabre.com (www.pierre-fabre.com)
  2. ^ anne.kerveillant@pierre-fabre.com (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/3183411_AE83411_0

The Weekend Times Magazine

Defacto Partner Visa Help from Best Immigration Lawyer AU

When two people decide to share their lives together, the legal paperwork shouldn’t get in the way. But if your relationship involves immigration, it often does. Australia’s partner visa process...

Why More Perth Homeowners Are Choosing Bidets for Modern Bathrooms

Bathroom renovations are no longer just about choosing stylish tiles, modern vanities and attractive tapware. Homeowners are increasingly considering how their bathrooms can support better hygiene, everyday comfort and long-term...

Does Sydney Australia Have a Good Nightlife Scene?

In the last several years, Sydney's nightlife has changed dramatically. The New South Wales state government adopted Draconian lockout regulations in 2014, forcing city center venues to close their doors...

The Role of Headless CMS in Modern Digital Architecture

With a constantly evolving digital architecture landscape, firms are continuously searching for novel avenues that guarantee nimbleness, flexibility, and scalability. A headless CMS sits front and center as one of...

Why External Blinds and Awnings Are Essential for Comfortable and Protected Outdoor Spaces

Creating outdoor areas that remain functional, comfortable, and visually appealing throughout the year requires effective protection from sun, wind, and changing weather. Installing external blinds and awnings provides a practical solution...

A Complete Guide to Hiring Shipping Containers

Shipping containers are used for transferring various types of products over long distances, usually from one country to another. They are also used as storage containers. But people who hire...

How Legal Representation Helps Solve Family Disputes

Family disputes can be some of the most challenging legal matters individuals face. Issues involving separation, parenting arrangements, property division, and family responsibilities often involve both legal complexities and emotional...

Accessible Kitchen Design in Perth: Building a Kitchen That Works for Everyone, Now and Later

The standard residential kitchen is designed for an able-bodied adult of average height who is standing while working. This design assumption is so deeply embedded in how kitchens are specified...

How TPD Solicitors Unlock Your Super Insurance Payout Fast

Up to 70% of Australians don't realize they have TPD insurance through their super, potentially missing out on life-changing payouts when they need them most. This staggering statistic reveals a...

hacklink esim new zealandBetimgrandpashabet girişzlibraryz libraryjojobetcialis 20 mg fiyat